Singapore Markets open in 1 hr 12 mins

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
615.24-0.87 (-0.14%)
At close: 04:00PM EST
613.42 -1.82 (-0.30%)
After hours: 06:53PM EST
Full screen
Trade prices are not sourced from all markets
Previous close616.11
Open616.02
Bid602.00 x 900
Ask616.00 x 1000
Day's range605.00 - 623.20
52-week range441.00 - 686.62
Volume791,993
Avg. volume754,190
Market cap66.165B
Beta (5Y monthly)0.18
PE ratio (TTM)9.84
EPS (TTM)62.53
Earnings date03 Feb 2022 - 07 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est715.68
  • Zacks

    Pfizer's (PFE) Cibinqo Gets FDA Nod for Atopic Dermatitis

    After a series of delays, Pfizer's (PFE) oral JAK inhibitor, Cibinqo (abrocitinib), gets approval for treating adults with atopic dermatitis in the United States.

  • Motley Fool

    2 Top Biotech Stocks to Buy and Hold for 10 Years

    With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna (NASDAQ: MRNA) and Regeneron (NASDAQ: REGN). Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market.

  • Zacks

    Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?

    Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.